18 March 2013 -- Commenting on AstraZeneca's decision to focus its UK R&D activities and move its headquarters to Cambridge, Steve Bates, BioIndustry Association (BIA) Chief Executive Officer, said:
"I am pleased that AstraZeneca has seen the value of the UK as a global hub for bioscience and we welcome its £330 million investment in consolidating its R&D activities and its global headquarters in Cambridge.
"AstraZeneca's decision recognises the strengths of the UK in terms of its science base, biotech capabilities and position as a leading centre for business."
For further information, please contact Robert Winder, Head of Communications, email@example.com, 020 7630 2191; mobile 07825 942 934.
Steve Bates, BIA Chief Executive Officer, is available for comment.
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org